ClinicalTrials.gg

Program

Alendronate

Also written as “alendronate”, “Comparator: alendronate” and “Liposomal Alendronate”.

Its studies are mostly in Osteoporosis, Postmenopausal · Osteoporosis · Osteitis Deformans · Coronary Stenosis · Back Pain, led by 8 companies.

Furthest: phase 4, since Aug 5, 200817 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Organon90 open or runningphase 4since Aug 5, 2008Sep 21, 2004none ahead
Viatris20 open or runningphase 1since Sep 21, 2009Sep 21, 2009none ahead
BIOrest10 open or runningphase 2since Aug 20, 2008Aug 20, 2008none ahead
Dr. Reddy's Laboratories10 open or runningphase 1since May 27, 2010May 27, 2010none ahead
Evangelisches Krankenhaus Lutherhaus gGmbH10 open or runningphase 3since Jan 11, 2012Jan 11, 2012none ahead
GlaxoSmithKline10 open or runningphase 4since May 18, 2006May 18, 2006none ahead
Radius Health10 open or runningphase 3since Jul 31, 2012Jul 31, 2012none ahead
Teva Pharmaceutical Industries10 open or runningphase 1since Jan 30, 2009Jan 30, 2009none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 21, 2004First studies: 3 phase 3 studies in Osteoporosis, PostmenopausalNew to OrganonOrganon · NCT00092040, NCT00092027, NCT00092014
  2. May 18, 2006GlaxoSmithKline's first study: phase 4 study in OsteoporosisNew to GlaxoSmithKlineGlaxoSmithKline · NCT00327990 · 300 enrolled · Netherlands
  3. Nov 10, 2006Phase 3 study in Osteoporosis, PostmenopausalOrganon · NCT00398931 · 1,099 enrolled
  4. May 30, 20072 phase 3 studiesOrganon · NCT00480766, NCT00480662
  5. Aug 5, 2008Phase 4 study in Osteoporosis, PostmenopausalOrganon · NCT00729651 · 343 enrolled
  6. Aug 20, 2008BIOrest's first study: phase 2 study in Coronary StenosisNew to BIOrestBIOrest · NCT00739466 · 226 enrolled · Israel
  7. Dec 4, 20082 phase 1 studies in OsteoporosisOrganon · NCT00803790, NCT00806416
  8. Jan 30, 2009Teva Pharmaceutical Industries's first study: phase 1 study in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00835406 · 140 enrolled · Canada
  9. Sep 21, 2009Viatris's first studies: 2 phase 1 studies in HealthyNew to ViatrisViatris · NCT01012934, NCT00983996
  10. May 27, 2010Dr. Reddy's Laboratories's first study: phase 1 study in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01133496 · 80 enrolled · India
  11. Jan 11, 2012Evangelisches Krankenhaus Lutherhaus gGmbH's first study: phase 3 study in OsteoporosisNew to Evangelisches Krankenhaus Lutherhaus gGmbHEvangelisches Krankenhaus Lutherhaus gGmbH · NCT01512446 · 436 enrolled · Germany
  12. Jul 31, 2012Radius Health's first study: phase 3 study in Osteoporosis, PostmenopausalNew to Radius HealthRadius Health · NCT01657162 · 1,139 enrolled · United States, Argentina, Brazil and more

TargetBeta

FDPS →read by rule
“Farnesyl diphosphate synthase inhibitor”ChEMBL 37, by rule

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT01657162Osteoporosis, Postmenopausal · United States, Argentina, Brazil and more3CompletedRadius HealthOct 3, 20161,139
NCT01512446Osteoporosis · Germany3TerminatedEvangelisches Krankenhaus Lutherhaus gGmbHMar 2013436
NCT01133496Healthy · India1CompletedDr. Reddy's LaboratoriesDec 200680
NCT01012934Healthy · United States1CompletedViatrisAug 2002110
NCT00983996Healthy · United States1CompletedViatrisJul 2002112
NCT00835406Healthy · Canada1CompletedTeva Pharmaceutical IndustriesJul 2000140
NCT00806416Osteoporosis1CompletedOrganonAug 2003244
NCT00803790Osteoporosis1CompletedOrganonJul 2006318
NCT00739466Coronary Stenosis · Israel2CompletedBIOrestDec 2015226
NCT00729651Osteoporosis, Postmenopausal4CompletedOrganonApr 10, 2009343
NCT00480766Osteoporosis3CompletedOrganonAug 2003173
NCT00480662Osteitis Deformans3CompletedOrganonOct 200260
NCT00398931Osteoporosis, Postmenopausal3CompletedOrganonOct 20031,099
NCT00327990Osteoporosis · Netherlands4CompletedGlaxoSmithKlineDec 2006300
NCT00092040Osteoporosis, Postmenopausal3CompletedOrganonOct 18, 2004936
NCT00092027Osteoporosis, Postmenopausal3CompletedOrganonMar 15, 2004454
NCT00092014Osteoporosis, Postmenopausal3CompletedOrganonApr 1, 20041,053

How it is read

Names in the registry

  • “Alendronate”, 7 entries
  • “alendronate”, 2 entries
  • “Comparator: alendronate”, 2 entries
  • “Liposomal Alendronate”, 2 entries
  • “Alendronate Sodium Tablets, 70 mg”, 2 entries

Codes read as this program: MK0217.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.